Rare diseases
Investigational molecules
Locations
305 Madison Avenue, 07960-6117, United States
Clinical research in pediatric hepatobiliary disease includes studies in children with biliary atresia after a successful Kasai procedure, with attention to liver transplantation, portal hypertension, and progression to end-stage liver disease.
Research activity in this area centers on clinical outcomes relevant to long-term liver health in a pediatric population with chronic biliary obstruction.
Intercept Pharmaceuticals Inc. runs clinical trials in conditions such as Primary biliary cholangitis, Congenital absence of bile ducts, Hepatitis alcoholic, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Study on Obeticholic Acid for Children with Biliary Atresia After Kasai Procedure
BelgiumStudy on the Long-Term Safety of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis
BelgiumStudy on the Effects of Bezafibrate and Obeticholic Acid for Patients with Primary Biliary Cholangitis
ItalyStudy on the Effects of INT-787 for Patients with Severe Alcohol-Associated Hepatitis
FranceStudy on the Effects of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis Who Cannot Tolerate Ursodeoxycholic Acid
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
